3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Stomach Neoplasms
7
Lymphoma, B-Cell, Marginal Zone
5
Gastritis
5
Lymphoma
4
Dyspepsia
4
Peptic Ulcer
3
Neoplasms
2
Stomach Ulcer
1
Skin Neoplasms
1
Pseudomyxoma Peritonei
1
Precancerous Gastric Lesions
1
Neutropenia
1
Neoplasms, Plasma Cell
1
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Large B-Cell, Diffuse
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Leukemia
1
Infections
1
Hematologic Neoplasms
1
Helicobacter Infections
1
Head and Neck Neoplasms
1
Glioblastoma
1
Gastritis Dyspepsia Helicobacter Pylori Infection Gastric Cancer Peptic Ulcer
1
Fever
1
Familial primary gastric lymphoma
1
Cystectomy
1
Chemotherapy Effect
1
Brain Neoplasms
1
Atrophy
1
Interventions
Dexamethasone
110
Cyclophosphamide
99
Melphalan
91
Bortezomib
68
Peripheral Blood Stem Cell Transplantation
63
Lenalidomide
57
fludarabine phosphate
55
Busulfan
53
Filgrastim
50
Antilymphocyte Serum
38
Tacrolimus
37
Thalidomide
36
Radiotherapy
36
Mycophenolic Acid
32
fludarabine
28
Cyclosporine
26
Methotrexate
25
Etoposide
22
Calcium Dobesilate
22
Prednisone
21
Whole-Body Irradiation
20
Methylprednisolone
20
sargramostim
19
pomalidomide
19
Granulocyte Colony-Stimulating Factor
18
carfilzomib
16
daratumumab
15
Cord Blood Stem Cell Transplantation
14
Carmustine
14
Rituximab
13
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Neoplasms, Plasma Cell
×
Amoxicillin
×
Clear all
NCT05678621
2024-04-19
RATIONALISE
Monash University
Phase 2/3
Recruiting
300 enrolled